Doripenem contraindications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Doripenem}} | {{Doripenem}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Contraindications== | ==Contraindications== | ||
DORIBAX® is contraindicated in patients with known serious hypersensitivity to doripenem or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta- | DORIBAX® is contraindicated in patients with known serious [[hypersensitivity]] to doripenem or to other drugs in the same class or in patients who have demonstrated [[anaphylactic]] reactions to [[beta-lactam]]s.<ref>{{Cite web | last = | first = |title =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf | publisher =|date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 22:11, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
DORIBAX® is contraindicated in patients with known serious hypersensitivity to doripenem or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.